Classification of dopamine antagonists using functional feature hypothesis and topological descriptors.

The designing of selective dopamine antagonists for their own subreceptors can be useful in individual therapy of various neuropsychiatric disorders. Three-dimensional pharmacophore hypothesis and two-dimensional topological descriptors were used to investigate and compare different classes of dopamine antagonists. The structurally diverse D(3) and D(4) antagonists above preclinical trials were selected to map common structural features of highly selective and efficacious antagonists. The generated pharmacophore hypotheses were successfully employed as discriminative probe for database screening. To filter out the false positive from screening hits, the classification models by two-dimensional topological descriptors were built. Molconn-Z and BCUT topological descriptors were employed to develop a classification model for 1328 dopamine antagonists from MDDR database. The soft independent modeling of class analogy and artificial neural network, two supervised classification techniques, successfully classified D(1), D(3), and D(4) antagonists at the average of 80% rates into their own active classes. The mean classification rates for D(2) antagonists were obtained to 60% due to insufficient selective D(2) antagonists. In this paper, we report the validity of our models generated using functional feature hypotheses and topological descriptors. The combining both of classification using functional feature hypotheses and topological descriptors would be a useful tool to predict selective antagonists.

[1]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[2]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[3]  H. Hall,et al.  The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions , 2004, Psychopharmacology.

[4]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[5]  Philip Seeman,et al.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.

[6]  J. Hagan,et al.  Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. , 2000, Journal of medicinal chemistry.

[7]  L. Hall,et al.  Molecular connectivity in chemistry and drug research , 1976 .

[8]  Kurt Hornik,et al.  Multilayer feedforward networks are universal approximators , 1989, Neural Networks.

[9]  Svante Wold,et al.  Pattern recognition by means of disjoint principal components models , 1976, Pattern Recognit..

[10]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[11]  Gerhard Klebe,et al.  A 3D QSAR Study on a Set of Dopamine D4 Receptor Antagonists , 2003, J. Chem. Inf. Comput. Sci..

[12]  M. Millan,et al.  S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors: II. Functional Profile and a Multiparametric Comparison with Haloperidol, Clozapine, and 11 Othe , 2000 .

[13]  Jonas Boström,et al.  A pharmacophore model for dopamine D4 receptor antagonists , 2000, J. Comput. Aided Mol. Des..

[14]  M. Millan,et al.  A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. , 1998, The Journal of pharmacology and experimental therapeutics.

[15]  Bruno Giros,et al.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA , 1991, Brain Research.

[16]  K. M. Smith,et al.  Novel software tools for chemical diversity , 1998 .

[17]  J. Hagan,et al.  Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists. , 1996, Journal of medicinal chemistry.

[18]  M. Millan,et al.  Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist. , 1999, Bioorganic & medicinal chemistry letters.

[19]  Lowell H. Hall Computational aspects of molecular connectivity and its role in structure-property modeling , 1990 .

[20]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  Jonathan S. Mason,et al.  Chemistry Space Metrics in Diversity Analysis, Library Design, and Compound Selection , 1998, J. Chem. Inf. Comput. Sci..

[22]  P. Seeman Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[23]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[24]  P. Strange,et al.  Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. , 2001, Pharmacological reviews.

[25]  S. Unger Molecular Connectivity in Structure–activity Analysis , 1987 .

[26]  D. Evans,et al.  Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. , 1993, European journal of pharmacology.

[27]  Yoshimasa Takahashi,et al.  Classification of Dopamine Antagonists Using TFS-Based Artificial Neural Network , 2004, J. Chem. Inf. Model..

[28]  J. Hagan,et al.  Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist. , 2003, Journal of medicinal chemistry.

[29]  Johann Gasteiger,et al.  Neural networks in chemistry and drug design , 1999 .